All Categories
Alzchem Group AG once again demonstrated its growth and earnings strength in the fiscal year 2025 in a continuing challenging industry environment.
Current results from the EMeRGE research project confirm triple benefits in practice
![[Translate to English:]](/fileadmin/_processed_/e/4/csm_csm_IMG_0840_bearbeitet_5e137ee253_8bb61fb1d2.png "[Translate to English:]")
On January 29, 2026, the kickoff event for the Alzchem Group’s leadership team took place.
Creapure®, the premium creatine “Made in Germany,” now presents itself on a completely redesigned website.
On Friday evening, Alzchem Group welcomed MEP Prof. Dr. Angelika Niebler and around 40 guests for a political dialogue.
The LIVADUR® product line is growing! From now on, LIVAGLUCO® brings a fresh breeze to the product range.
Anyone working at Alzchem receives more than just a secure job – they benefit from a comprehensive health program that truly stands out.
At its December meeting, the Supervisory Board of Alzchem Group AG took an important step toward ensuring the continuity and future growth of the company: it was decided to extend the employment contracts of CEO Andreas Niedermaier and CFO Andreas Lösler, which were due to expire at the end of 2026, ahead of schedule.